Commercial revenue for the full-year 2025 is expected to be in the range of $100M-$106M, reflecting growth of approximately 55%-65% over the projected full-year 2024 commercial revenue. Updating previous guidance, the company now expects to achieve cashflow break-even and GAAP profitability in Q4 2025, instead of Q3 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCEL:
- ServiceNow initiated, Brinker upgraded: Wall Street’s top analyst calls
- Cantor Fitzgerald bullish on Avita Medical after FDA approval for RECELL GO Mini
- Avita Medical initiated with a Buy at D. Boral Capital
- Closing Bell Movers: International Seaways up 8% on S&P600 inclusion
- Avita Medical discloses FDA premarket approval for ECELL GO mini